Cutaneous melanoma, frequently driven by BRAF (V600X) mutations, often develops resistance to mitogen-activated protein kinase (MAPK)-targeted therapies and immune checkpoint inhibitors. In this issue of Cancer Cell, Lubrano et al. identify RhoA-FAK-AKT signaling as a resistance mechanism and demonstrate that combining RAF-MEK glue with a FAK inhibitor enhances tumor regression and immune response.